GSA Capital Partners LLP Sells 8,440 Shares of Hims & Hers Health, Inc. (NYSE:HIMS)

GSA Capital Partners LLP decreased its holdings in Hims & Hers Health, Inc. (NYSE:HIMS) by 19.4% during the 3rd quarter, HoldingsChannel.com reports. The firm owned 35,101 shares of the company’s stock after selling 8,440 shares during the period. GSA Capital Partners LLP’s holdings in Hims & Hers Health were worth $647,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of HIMS. Swiss National Bank grew its stake in shares of Hims & Hers Health by 0.7% in the first quarter. Swiss National Bank now owns 281,500 shares of the company’s stock worth $4,355,000 after purchasing an additional 2,000 shares during the last quarter. Sei Investments Co. grew its stake in shares of Hims & Hers Health by 206.9% in the first quarter. Sei Investments Co. now owns 56,202 shares of the company’s stock worth $869,000 after purchasing an additional 37,890 shares during the last quarter. Avantax Advisory Services Inc. bought a new stake in shares of Hims & Hers Health in the first quarter worth $156,000. ProShare Advisors LLC grew its stake in shares of Hims & Hers Health by 10.0% in the first quarter. ProShare Advisors LLC now owns 22,257 shares of the company’s stock worth $344,000 after purchasing an additional 2,023 shares during the last quarter. Finally, Vanguard Group Inc. grew its stake in shares of Hims & Hers Health by 1.0% in the first quarter. Vanguard Group Inc. now owns 14,310,192 shares of the company’s stock worth $221,379,000 after purchasing an additional 136,907 shares during the last quarter. Institutional investors own 63.52% of the company’s stock.

Insider Buying and Selling

In other Hims & Hers Health news, CEO Andrew Dudum sold 188,888 shares of the company’s stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $14.56, for a total value of $2,750,209.28. Following the completion of the sale, the chief executive officer now directly owns 33,502 shares of the company’s stock, valued at approximately $487,789.12. This represents a 84.94 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CFO Oluyemi Okupe sold 142,886 shares of the company’s stock in a transaction dated Wednesday, November 13th. The stock was sold at an average price of $29.93, for a total transaction of $4,276,577.98. Following the completion of the sale, the chief financial officer now directly owns 112,186 shares of the company’s stock, valued at $3,357,726.98. The trade was a 56.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 996,961 shares of company stock worth $20,256,416 in the last quarter. Insiders own 17.71% of the company’s stock.

Hims & Hers Health Trading Up 8.7 %

Shares of NYSE HIMS opened at $21.01 on Tuesday. The firm’s 50-day moving average price is $19.90 and its 200-day moving average price is $18.98. Hims & Hers Health, Inc. has a 1-year low of $7.50 and a 1-year high of $30.44. The firm has a market capitalization of $4.51 billion, a P/E ratio of 47.75 and a beta of 1.06.

Hims & Hers Health (NYSE:HIMS) last posted its earnings results on Monday, November 4th. The company reported $0.32 earnings per share for the quarter, topping analysts’ consensus estimates of $0.06 by $0.26. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The company had revenue of $401.56 million for the quarter, compared to analyst estimates of $382.20 million. During the same quarter in the prior year, the business posted ($0.04) EPS. The firm’s revenue was up 77.1% compared to the same quarter last year. Equities research analysts forecast that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on the stock. Piper Sandler reissued a “neutral” rating and issued a $21.00 price objective (up previously from $18.00) on shares of Hims & Hers Health in a research note on Tuesday, November 5th. Imperial Capital lowered shares of Hims & Hers Health from an “outperform” rating to an “in-line” rating in a report on Friday, August 9th. TD Cowen boosted their target price on shares of Hims & Hers Health from $25.00 to $28.00 and gave the company a “buy” rating in a report on Friday, November 8th. Needham & Company LLC began coverage on shares of Hims & Hers Health in a report on Thursday, August 22nd. They issued a “buy” rating and a $24.00 target price on the stock. Finally, Bank of America lowered shares of Hims & Hers Health from a “buy” rating to an “underperform” rating and dropped their target price for the company from $32.00 to $18.00 in a report on Thursday, November 14th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $20.71.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.